Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year
News
The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the safety and biological activity of Amylyx Pharmaceuticals‘ investigational therapy ... Read more